Disrupting the Cell Therapy Market: Nucleus Biologics Brings Transparency, Customization & Control

21 Jun 2021

We are honored to be featured in an interview with Bioinformant!

In recent years, the cell culture company Nucleus Biologics has been at the forefront of market disruption. In this interview with David Sheehan (CEO), we explore how the company has been growing its team, expanding its production capabilities, launching new products, and impressively, rolling out the world’s first online portal for instantaneous custom cGMP cell culture media configuration.

The pace never slows when your mission is to enable lifesaving science!

Cade: Tell us what Nucleus Biologics has been up to since the last time we spoke in 2018?

David Sheehan: First Cade, thank you for checking in on us.  I would remiss if I didn’t highlight Bioinformant’s growth in readership and vital contribution as an information source for cell and gene therapy. Thank you.

It has been an amazing two years. We continue driving reproducibility by innovating new products supported with good science.

A few highlights:

First, the team has grown dramatically and we have added some industry heavyweights in key areas.

Read the full interview here

Share this article

Brad N. Taylor, Ph.D.
Dr. Brad Taylor has 17 years of experience commercializing products for scientists in both academia and industry before joining Nucleus Biologics. Most recently, Dr. Taylor was the Director of Global Marketing at HemaCare, supporting the needs of the cellular therapy industry. Prior to HemaCare, Dr. Taylor spent 11 years at PerkinElmer supporting in vivo imaging platforms and has held leadership roles in technical support, product management, and marketing. Dr. Taylor holds a M.S. in Microbiology and Immunology from Louisiana State University Health Sciences Center and a Ph.D. in Molecular Biology and Genetics from Friedrich-Alexander University in Germany.